Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $11 from $10 and keeps an Overweight rating on the shares. The company’s Q4 products beats consensus estimates, driven by strong IL2 sales growth, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance upgraded to Outperform from Market Perform at Citizens
- Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan
- Iovance Biotherapeutics: Strengthening Commercial Momentum and Expanding Amtagvi Runway Support Buy Rating
- Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership
- Unusually active option classes on open February 24th